A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 207,100 shares of LRMR stock, worth $820,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares
207,100
Previous 603,581 65.69%
Holding current value
$820,116
Previous $4.38 Million 69.01%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.3 - $10.68 $2.5 Million - $4.23 Million
-396,481 Reduced 65.69%
207,100 $1.36 Million
Q2 2024

Aug 14, 2024

BUY
$6.33 - $9.89 $1.05 Million - $1.63 Million
165,181 Added 37.68%
603,581 $4.38 Million
Q1 2024

May 15, 2024

SELL
$4.2 - $13.28 $50,400 - $159,360
-12,000 Reduced 2.66%
438,400 $3.33 Million
Q4 2023

Feb 14, 2024

SELL
$2.35 - $4.71 $10,810 - $21,666
-4,600 Reduced 1.01%
450,400 $2.05 Million
Q3 2023

Nov 14, 2023

SELL
$3.08 - $4.49 $1.18 Million - $1.72 Million
-384,000 Reduced 45.77%
455,000 $1.8 Million
Q2 2023

Aug 14, 2023

BUY
$3.13 - $5.27 $1.2 Million - $2.02 Million
384,000 Added 84.4%
839,000 $2.63 Million
Q1 2023

May 15, 2023

SELL
$4.0 - $6.68 $80,000 - $133,600
-20,000 Reduced 4.21%
455,000 $2.06 Million
Q3 2022

Nov 14, 2022

BUY
$1.53 - $3.64 $726,750 - $1.73 Million
475,000 New
475,000 $1.52 Million
Q1 2022

May 16, 2022

SELL
$3.65 - $10.84 $718,670 - $2.13 Million
-196,896 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$9.61 - $15.11 $939,242 - $1.48 Million
97,736 Added 98.56%
196,896 $2.27 Million
Q2 2021

Aug 16, 2021

BUY
$8.0 - $15.2 $655,200 - $1.24 Million
81,900 Added 474.51%
99,160 $974,000
Q2 2020

Aug 14, 2020

BUY
$0.72 - $16.76 $12,427 - $289,277
17,260 New
17,260 $222,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $171M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.